Ryan Livingston

A technology review from the University of Virginia analyzes the successes of AID devices, as well as indicating where the technology still has to go.

Lexicon aims to address concerns from a 2024 complete response letter, which cited an increased risk of diabetic ketoacidosis.

Semaglutide exhibited a 57% reduction in major adverse cardiovascular events compared to tirzepatide in patients with CVD with no prior history of diabetes.

Despite not lowering cardiovascular death or worsening heart failure, composite data did suggest the efficacy of in-hospital initiation of SGLT2 inhibitors.

A lower incidence of all-cause mortality and hospitalization for worsening heart failure proved digitoxin’s noninferiority in this phase 4 trial.

A recap 8 clinical trials in cardiovascular care to know from the European Society of Cardiology Congress 2025.

Patients with hypercholesterolemia on individualized maximally tolerated dose of statins achieved guideline-recommended LDL-C levels on inclisiran.

Despite an excellent safety and tolerability profile and proven efficacy in treating atrial fibrillation, PFA failed to prove superiority to RA.

Merck’s investigational oral PCSK9 inhibitor reduced LDL-C, non-HDL-C, ApoB, and LP(a) significantly compared to placebo after 24 weeks.

Ionis Therapeutics, Inc. also announced plans to submit an sNDA for olezarsen based on these trial results by the end of 2025.

The investigative aldosterone synthase inhibitor reduced seated systolic blood pressure in patients with uncontrolled or resistant hypertension compared to placebo.

Aficamten displayed superior improvements in peak oxygen uptake and hemodynamics compared to the most commonly used beta-blocker for symptomatically obstructive HCM.

The 2025 Concise Clinical Guidance also aims to assuage vaccine hesitancy and resistance, provide better education, and overcome barriers to implementation.

Recent research has shown a reduction of nearly 1/3 in type 2 diabetes risk associated with adherence to a Mediterranean diet, calorie reduction, and moderate exercise.

Outlook Therapeutics has expressed plans to meet with the FDA to address regulatory issues, as well as expand into European markets.

Perceived changes in glucose metabolism and regulation in turn lead to more severe reported menopausal symptoms.

A brief history of intravitreal implants; where we started and how far we can still go to reduce treatment burden for patients and clinicians alike.

Take a look at 7 major clinical trials to keep an eye on for the upcoming ESC Congress from August 29-September 1, 2025.

If approved, the investigative therapy could provide a frontline treatment for patients with SAA who do not have matched sibling donors for cell transplantation.

A recent analysis utilizing the AHA’s PREVENT equations has found 11.8 million US adults aged 40 to 75 had a 10-year ASCVD risk of 5% or greater.

Investigators have cited population growth and epidemiological improvements as leading causes for the significant jump in cases.

Preliminary findings have also indicated an association between an evolocumab add-on to statin therapy and stenosis degree reduction.

With positive topline phase 2 results, parent company Crinetics Pharmaceuticals, Inc., has announced plans to begin phase 3 testing in the second half of 2025.

According to investigators, individuals with 3 or more risk factors for metabolic syndrome have a 40% greater risk of developing Parkinson’s.

A series of phase 2/3 trials collectively indicate the overall lipid-lowering effects of obicetrapib in a 5 mg dose, a 10 mg dose, and 10 mg with ezetimibe.

New research shines a light on the liver’s role in cardiovascular disease prevention, indicating a potential new predictor for coronary heart disease.

A recent study from Korea has drawn connections between sleep duration and regularity and major adverse cardiovascular events.

This HCPLive Five episode focuses on 5 key ophthalmology updates from the ASRS2025 conference.

The TITRATE-HF study highlights the importance of early and intensive use of guideline-recommended medical therapy, focusing on dose titration.